Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

JPC0661

Catalog No. T215131 Copy Product Info
🥰Excellent
JPC0661 is a direct and allosteric inhibitor of ΔFOSB. It inhibits the binding of ΔFOSB/JUND and ΔFOSB to DNA with a micromolar IC50 value (9-52 μM), and directly suppresses ΔFOSB-mediated transcription in vitro with an IC50 of 0.82 μM. In vivo, JPC0661 notably reduces the occupancy of ΔFOSB at genomic AP1 sites. JPC0661 disrupts the formation of the ΔFOSB/JUND-DNA complex by binding to a novel groove outside the ΔFOSBDNA binding cleft. JPC0661 is applicable in Alzheimer's disease research.

JPC0661

Copy Product Info
🥰Excellent
Catalog No. T215131

JPC0661 is a direct and allosteric inhibitor of ΔFOSB. It inhibits the binding of ΔFOSB/JUND and ΔFOSB to DNA with a micromolar IC50 value (9-52 μM), and directly suppresses ΔFOSB-mediated transcription in vitro with an IC50 of 0.82 μM. In vivo, JPC0661 notably reduces the occupancy of ΔFOSB at genomic AP1 sites. JPC0661 disrupts the formation of the ΔFOSB/JUND-DNA complex by binding to a novel groove outside the ΔFOSBDNA binding cleft. JPC0661 is applicable in Alzheimer's disease research.

JPC0661
Cas No. 30479-81-3
Pack SizePriceUSA StockGlobal StockQuantity
10 mgInquiry10-14 weeks10-14 weeks
50 mgInquiry10-14 weeks10-14 weeks
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
JPC0661 is a direct and allosteric inhibitor of ΔFOSB. It inhibits the binding of ΔFOSB/JUND and ΔFOSB to DNA with a micromolar IC50 value (9-52 μM), and directly suppresses ΔFOSB-mediated transcription in vitro with an IC50 of 0.82 μM. In vivo, JPC0661 notably reduces the occupancy of ΔFOSB at genomic AP1 sites. JPC0661 disrupts the formation of the ΔFOSB/JUND-DNA complex by binding to a novel groove outside the ΔFOSBDNA binding cleft. JPC0661 is applicable in Alzheimer's disease research.
In vitro
JPC0661 (0-100 μM) modulates ΔFOSB-driven gene expression with an IC50 of 0.82 μM and induces ΔFOSB protein accumulation in HEK293 cells. At concentrations of 0-100 μM for 24 or 72 hours, JPC0661 demonstrates good tolerability in neural progenitor cells, AP1-luc HEK293 cells, and Neuro2A cells.
In vivo
JPC0661 (50 μM, administered at a rate of 16.7 ng/h over 3 days) significantly and broadly decreases the binding of ΔFOSB at most normal genomic binding sites in male and female heterozygous transgenic mice expressing human amyloid precursor protein (APP) with Swedish (K670N, M671L) and Indiana (V717F) mutations.
Chemical Properties
Molecular Weight347.35
FormulaC15H13N3O5S
Cas No.30479-81-3
SmilesO=C1N(N=C(N)C1)C2=CC=C(OC=3C=CC=CC3)C(=C2)S(=O)(=O)O
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy JPC0661 | purchase JPC0661 | JPC0661 cost | order JPC0661 | JPC0661 in vivo | JPC0661 in vitro | JPC0661 formula | JPC0661 molecular weight